
Allergan has agreed to buy clinical-stage biotech Vitae Pharmaceuticals for $639 million, or $21 a share – more than double …
US biopharmaceutical company Vitae Pharmaceuticals has appointed Christine Brennan chief business officer. She has over 10 years industry experience and …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

